The University of Queensland

Advances in Cardiovascular Diagnostics Use of Cardiac Biomarkers in Clinical Research and Care of the Patient

Effron, Mark B. and Khan, Zahoor (2019). Advances in Cardiovascular Diagnostics Use of Cardiac Biomarkers in Clinical Research and Care of the Patient. Handbook of Biomarkers and Precision Medicine. (pp. 501-513) edited by Carini, C., Fidock, M. and VanGool, A.. Boca Raton, FL United States: CRC Press.

Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease

Marquis‐Gravel, Guillaume, Stebbins, Amanda, Wruck, Lisa M., Roe, Matthew T., Effron, Mark B., Hammill, Bradley G., Whittle, Jeff, VanWormer, Jeffrey J., Robertson, Holly R., Alikhaani, Jacqueline D., Kripalani, Sunil, Farrehi, Peter M., Girotra, Saket, Benziger, Catherine P., Polonsky, Tamar S., Merritt, J. Greg, Gupta, Kamal, McCormick, Thomas E., Knowlton, Kirk U., Jain, Sandeep K., Kochar, Ajar, Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association. doi: 10.1161/jaha.122.026921

Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based data

Jafari, Eissa, Cooper-DeHoff, Rhonda M., Effron, Mark B., Hogan, William R. and McDonough, Caitrin W. (2024). Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based data. American Journal of Hypertension, 37 (1), 60-68. doi: 10.1093/ajh/hpad084

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial

Narcisse, Dennis I., Kim, Hwasoon, Wruck, Lisa M., Stebbins, Amanda L., Muñoz, Daniel, Kripalani, Sunil, Effron, Mark B., Gupta, Kamal, Anderson, R. David, Jain, Sandeep K., Girotra, Saket, Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Polonsky, Tamar S., Ahmad, Faraz S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care, 47 (1), 81-88. doi: 10.2337/dc23-0749

More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?

McKinnie, Christopher M. and Effron, Mark B. (2023). More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?. Mayo Clinic Proceedings, 98 (11), 1590-1592. doi: 10.1016/j.mayocp.2023.09.014

Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in patients treated with P2Y12 inhibitors

Girotra, Saket, Stebbins, Amanda, Wruck, Lisa, Marquis‐Gravel, Guillaume, Gupta, Kamal, Farrehi, Peter, Benziger, Catherine P., Effron, Mark B., Whittle, Jeffrey, Muñoz, Daniel, Kripalani, Sunil, Anderson, R. David, Jain, Sandeep K., Polonsky, Tamar S., Ahmad, Faraz S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2023). Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in patients treated with P2Y12 inhibitors. Journal of the American Heart Association, 12 (20) e030385, 1-10. doi: 10.1161/jaha.123.030385

Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease : A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial

Sleem, Amber, Effron, Mark B., Stebbins, Amanda, Wruck, Lisa M., Marquis-Gravel, Guillaume, Muñoz, Daniel, Re, Richard N., Gupta, Kamal, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, Whittle, Jeffrey, Benziger, Catherine P., Farrehi, Peter M., Knowlton, Kirk U., Polonsky, Tamar S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Jones, W. Schuyler and Hernandez, Adrian F. (2023). Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease : A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiology, 8 (11), 1061-1069. doi: 10.1001/jamacardio.2023.3364

Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE

Gupta, Kamal, Mehta, Harsh, Kim, Hwasoon, Stebbins, Amanda, Wruck, Lisa M., Muñoz, Daniel, Effron, Mark B., Anderson, R. David, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, DeWalt, Darren A., Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Knowlton, Kirk U., Polonsky, Tamar S., Bradley, Steven M., Harrington, Robert A., Rothman, Russell L., Jones, W. Schuyler and Hernandez, Adrian F. (2023). Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. American Heart Journal, 264, 31-39. doi: 10.1016/j.ahj.2023.06.001

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Chiarito, Mauro, Cao, Davide, Sartori, Samantha, Zhang, Zhongjie, Vogel, Birgit, Spirito, Alessandro, Smith, Kenneth F., Weintraub, William, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Effron, Mark B., Stefanini, Giulio, Keller, Stuart, Kapadia, Samir, Rao, Sunil V., Henry, Timothy D., Pocock, Stuart, Sharma, Samin, Dangas, George, Kini, Annapoorna, Baber, Usman and Mehran, Roxana (2023). Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. European Heart Journal: Acute Cardiovascular Care, 12 (9), 594-603. doi: 10.1093/ehjacc/zuad083

Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 Trial

Hess, Connie N., Hsia, Judith, Carroll, Ian A., Nehler, Mark R., Ruf, Wolfram, Morrow, David A., Nicolau, Jose C., Berwanger, Otavio, Szarek, Michael, Capell, Warren H., Johri, Shilpa, Pursley, Michael S., Gupta, Ryan, Meehan, Patrick S., Franchi, Francesco, Effron, Mark B., Marshall, Debra, Graybill, Christopher A., Graybill, Sophie P., Keuer, Thomas, Bristow, Michael R. and Bonaca, Marc P. (2023). Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 43 (8), 1572-1582. doi: 10.1161/atvbaha.122.318748

Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE study

Shen, Rebecca, Mulder, Hillary, Wruck, Lisa, Weissler, E. Hope, Robertson, Holly R., Sharlow, Amber G., Kripalani, Sunil, Muñoz, Daniel, Effron, Mark B., Gupta, Kamal, Girotra, Saket, Whittle, Jeff, Benziger, Catherine P., VanWormer, Jeffrey J., Polonsky, Tamar S., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2023). Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE study. Journal of the American Heart Association, 12 (13) e027899, 1-18. doi: 10.1161/jaha.122.027899

Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale

Joseph, Jacob, Pajewski, Nicholas M., Dolor, Rowena J., Sellers, Mary Ann, Perdue, Letitia H., Peeples, Sheronda R., Henrie, Adam M., Woolard, Nancy, Jones, W. Schuyler, Benziger, Catherine P., Orkaby, Ariela R., Mixon, Amanda S., VanWormer, Jeffrey J., Shapiro, Michael D., Kistler, Christine E., Polonsky, Tamar S., Chatterjee, Ranee, Chamberlain, Alanna M., Forman, Daniel E., Knowlton, Kirk U., Gill, Thomas M., Newby, L. Kristin, Hammill, Bradley G., Cicek, Mine S., Williams, Neely A., Decker, Jake E., Ou, Jiafu, Rubinstein, Jack, Choudhary, Gaurav ... Ramalingam, Ramesh (2023). Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. Journal of the American Geriatrics Society, 71 (6), 1701-1713. doi: 10.1111/jgs.18312

Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solution

Obi, Koyenum and Effron, Mark B. (2022). Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solution. Mayo Clinic Proceedings, 97 (12), 2180-2183. doi: 10.1016/j.mayocp.2022.10.015

Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock

Effron, Mark B. (2022). Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock. Mayo Clinic Proceedings, 97 (6), 1041-1043. doi: 10.1016/j.mayocp.2022.04.012

Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatients

Rizk, John G., Lazo, Jose G., Gupta, Aashish, Lavie, Carl J. and Effron, Mark B. (2022). Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatients. Seminars in Thrombosis and Hemostasis, 49 (01), 085-088. doi: 10.1055/s-0042-1750024

To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years

Rizk, John G., Gupta, Aashish, Lazo, Jose G., Sardar, Partha, Henry, Brandon Michael, Lavie, Carl J. and Effron, Mark B. (2022). To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Seminars in Thrombosis and Hemostasis, 49 (01), 062-072. doi: 10.1055/s-0042-1744302

Therapeutic anticoagulation with heparin in critically ill patients with covid-19

Goligher, Ewan C., Bradbury, Charlotte A., McVerry, Bryan J., Lawler, Patrick R., Berger, Jeffrey S., Gong, Michelle N., Carrier, Marc, Reynolds, Harmony R., Kumar, Anand, Turgeon, Alexis F., Kornblith, Lucy Z., Kahn, Susan R., Marshall, John C., Kim, Keri S., Houston, Brett L., Derde, Lennie P.G., Cushman, Mary, Tritschler, Tobias, Angus, Derek C., Godoy, Lucas C., McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E., Brooks, Maria M., Lewis, Roger J., Berry, Lindsay R., Lorenzi, Elizabeth, Gordon, Anthony C., Berry, Scott M. ... The REMAP-CAP, ACTIV-4a, and ATTACC Investigators (2021). Therapeutic anticoagulation with heparin in critically ill patients with covid-19. New England Journal of Medicine, 385 (9), 777-789. doi: 10.1056/NEJMoa2103417

Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

Lawler, Patrick R., Goligher, Ewan C., Berger, Jeffrey S., Neal, Matthew D., McVerry, Bryan J., Nicolau, Jose C., Gong, Michelle N., Carrier, Marc, Rosenson, Robert S., Reynolds, Harmony R., Turgeon, Alexis F., Escobedo, Jorge, Huang, David T., Bradbury, Charlotte A., Houston, Brett L., Kornblith, Lucy Z., Kumar, Anand, Kahn, Susan R., Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S., Kim, Keri S., Gordon, Anthony C., Kirwan, Bridget-Anne, Brooks, Maria M., Higgins, Alisa M., Lewis, Roger J., Lorenzi, Elizabeth, Berry, Scott M. ... The ATTACC, ACTIV-4a, and REMAP-CAP Investigators (2021). Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. New England Journal of Medicine, 385 (9), 790-802. doi: 10.1056/NEJMoa2105911

Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trial

Kochar, Ajar, Summers, Mary B., Benziger, Catherine P., Marquis-Gravel, Guillaume, DeWalt, Darren A., Pepine, Carl J., Gupta, Kamal, Bradley, Steven M., Dodson, John A., Lampert, Brent C., Robertson, Holly, Polonsky, Tamar S., Jones, W. Schuyler and Effron, Mark B (2021). Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trial. Clinical Trials, 18 (4), 449-456. doi: 10.1177/1740774520988838

Comparative effectiveness of aspirin dosing in cardiovascular disease

Jones, W. Schuyler, Mulder, Hillary, Wruck, Lisa M., Pencina, Michael J., Kripalani, Sunil, Muñoz, Daniel, Crenshaw, David L., Effron, Mark B., Re, Richard N., Gupta, Kamal, David Anderson, R., Pepine, Carl J., Handberg, Eileen M., Manning, Brittney R., Jain, Sandeep K., Girotra, Saket, Riley, Danielle, DeWalt, Darren A., Whittle, Jeff, Goldberg, Ythan H., Roger, Veronique L., Hess, Rachel, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Ford, Daniel E., Haynes, Kevin, VanWormer, Jeffrey J., Knowlton, Kirk U. ... for the ADAPTABLE Team (2021). Comparative effectiveness of aspirin dosing in cardiovascular disease. New England Journal of Medicine, 384 (21), 1981-1990. doi: 10.1056/NEJMoa2102137

Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study

Chandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Aquino, Melissa, Moalem, Kamilia, Kini, Annapoorna S., Rao, Sunil V., Weintraub, William, Henry, Timothy D., Vogel, Birgit, Ge, Zhen, Muhlestein, Joseph B., Weiss, Sandra, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Claessen, Bimmer E., Keller, Stuart, Baker, Brian A., Effron, Mark B., Pocock, Stuart, Dangas, George, Kapadia, Samir and Mehran, Roxana (2020). Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clinical Research in Cardiology, 109 (6), 725-734. doi: 10.1007/s00392-019-01561-4

Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry

Chandiramani, Rishi, Chen, Huazhen, Aoi, Shunsuke, Giustino, Gennaro, Claessen, Bimmer, Sartori, Samantha, Aquino, Melissa, Sorrentino, Sabato, Cao, Davide, Goel, Ridhima, Kini, Annapoorna, Rao, Sunil, Weintraub, William, Henry, Timothy D., Kapadia, Samir, DeFranco, Anthony, Muhlestein, Joseph B., Toma, Catalin, Effron, Mark B., Keller, Stuart, Baker, Brian A., Pocock, Stuart, Baber, Usman and Mehran, Roxana (2020). Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 95 (5) ccd.28369, 885-892. doi: 10.1002/ccd.28369

Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial

Marquis-Gravel, Guillaume, Roe, Matthew T., Robertson, Holly R., Harrington, Robert A., Pencina, Michael J., Berdan, Lisa G., Hammill, Bradley G., Faulkner, Madelaine, Muñoz, Daniel, Fonarow, Gregg C., Nallamothu, Brahmajee K., Fintel, Dan J., Ford, Daniel E., Zhou, Li, Daugherty, Sarah E., Nauman, Elizabeth, Kraschnewski, Jennifer, Ahmad, Faraz S., Benziger, Catherine P., Haynes, Kevin, Merritt, J. Greg, Metkus, Thomas, Kripalani, Sunil, Gupta, Kamal, Shah, Raj C., McClay, James C., Re, Richard N., Geary, Carol, Lampert, Brent C. ... Jones, W. Schuyler (2020). Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiology, 5 (5) 0116, 598-607. doi: 10.1001/jamacardio.2020.0116

Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: insights from the TRANSLATE ACS study

Ibrahim, Homam, Kaltenbach, Lisa A., Hess, Connie N., Recchia, Tammy, Effron, Mark B., Stone, Gregg W. and Wang, Tracy Y. (2019). Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: insights from the TRANSLATE ACS study. Catheterization and Cardiovascular Interventions, 93 (4), E204-E210. doi: 10.1002/ccd.27816

The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry

Ge, Zhen, Baber, Usman, Claessen, Bimmer E., Farhan, Serdar, Chandrasekhar, Jaya, Li, Shawn X., Sartori, Samantha, Kini, Annapoorna S., Rao, Sunil V., Weiss, Sandra, Henry, Timothy D., Vogel, Birgit, Sorrentino, Sabato, Faggioni, Michela, Kapadia, Samir, Muhlestein, Brent, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Effron, Mark B., Keller, Stuart, Baker, Brian A., Pocock, Stuart, Dangas, George and Mehran, Roxana (2019). The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 93 (3), E112-E119. doi: 10.1002/ccd.27860

Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes

Faggioni, Michela, Baber, Usman, Chandrasekhar, Jaya, Sartori, Samantha, Weintraub, William, Rao, Sunil V., Vogel, Birgit, Claessen, Bimmer, Kini, Annapoorna, Effron, Mark, Ge, Zhen, Keller, Stuart, Strauss, Craig, Snyder, Clayton, Toma, Catalin, Weiss, Sandra, Aquino, Melissa, Baker, Brian, Defranco, Anthony, Bansilal, Sameer, Muhlestein, Brent, Kapadia, Samir, Pocock, Stuart, Poddar, Kanhaiya L., Henry, Timothy D. and Mehran, Roxana (2019). Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 94 (1), 53-60. doi: 10.1002/ccd.28033

Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study

Chandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Aquino, Melissa, Kini, Annapoorna S., Rao, Sunil, Weintraub, William, Henry, Timothy D., Farhan, Serdar, Vogel, Birgit, Sorrentino, Sabato, Ge, Zhen, Kapadia, Samir, Muhlestein, Joseph B., Weiss, Sandra, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Effron, Mark B., Keller, Stuart, Baker, Brian A., Pocock, Stuart, Dangas, George and Mehran, Roxana (2018). Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Canadian Journal of Cardiology, 34 (3), 319-329. doi: 10.1016/j.cjca.2017.12.023

Antiplatelet therapy changes for patients with myocardial infarction with recurrent ischemic events: Insights into contemporary practice from the TRANSLATE-ACS (treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary syndrome) study

Fanaroff, Alexander C., Kaltenbach, Lisa A., Peterson, Eric D., Akhter, Mohammed W., Effron, Mark B., Henry, Timothy D. and Wang, Tracy Y. (2018). Antiplatelet therapy changes for patients with myocardial infarction with recurrent ischemic events: Insights into contemporary practice from the TRANSLATE-ACS (treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary syndrome) study. Journal of the American Heart Association, 7 (4) e007982. doi: 10.1161/JAHA.117.007982

The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: insights from the TRANSLATE-ACS study

Effron, Mark B., Wang, Tracy Y., Fonarow, Gregg C., Henry, Timothy D., Zettler, Marjorie E., Baker, Brian A., McCoy, Lisa A. and Peterson, Eric D. (2018). The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: insights from the TRANSLATE-ACS study. Catheterization and Cardiovascular Interventions, 91 (2), 242-250. doi: 10.1002/ccd.27145

The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease – Where Is the Moon Now?

Effron, Mark B. and Gibson, C. Michael (2018). The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease – Where Is the Moon Now?. Progress in Cardiovascular Diseases, 60 (4-5), 457-459. doi: 10.1016/j.pcad.2018.01.011

One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database

Effron, Mark B., Nair, Kavita V., Molife, Cliff, Keller, Stuart Y., Page, Robert L., Simeone, Jason C., Murphy, Brian, Nordstrom, Beth L., Zhu, Yajun, McCollam, Patrick L. and Vetrovec, George W. (2017). One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database. American Journal of Cardiovascular Drugs , 18 (2), 129-141. doi: 10.1007/s40256-017-0255-y

Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study

Baber, Usman, Chandrasekhar, Jaya, Sartori, Samantha, Aquino, Melissa, Kini, Annapoorna S., Kapadia, Samir, Weintraub, William, Muhlestein, Joseph B., Vogel, Birgit, Faggioni, Michela, Farhan, Serdar, Weiss, Sandra, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Baker, Brian A., Keller, Stuart, Effron, Mark B., Henry, Timothy D., Rao, Sunil, Pocock, Stuart, Dangas, George and Mehran, Roxana (2017). Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC: Cardiovascular Interventions, 10 (20), 2017-2025. doi: 10.1016/j.jcin.2017.02.047

Multivessel versus culprit vessel-only percutaneous coronary intervention among patients with acute myocardial infarction: Insights from the TRANSLATE-ACS observational study

Ibrahim, Homam, Sharma, Praneet K., Cohen, David J., Fonarow, Gregg C., Kaltenbach, Lisa A., Effron, Mark B., Zettler, Marjorie E., Peterson, Eric D. and Wang, Tracy Y. (2017). Multivessel versus culprit vessel-only percutaneous coronary intervention among patients with acute myocardial infarction: Insights from the TRANSLATE-ACS observational study. Journal of the American Heart Association, 6 (10) e006343. doi: 10.1161/JAHA.117.006343

Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction a secondary analysis of the TRANSLATE-ACS study

Guimarães, Patricia O., Krishnamoorthy, Arun, Kaltenbach, Lisa A., Anstrom, Kevin J., Effron, Mark B., Mark, Daniel B., McCollam, Patrick L., Davidson-Ray, Linda, Peterson, Eric D. and Wang, Tracy Y. (2017). Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction a secondary analysis of the TRANSLATE-ACS study. JAMA Cardiology, 2 (7), 750-757. doi: 10.1001/jamacardio.2017.1460

Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study

Baber, Usman, Sartori, Samantha, Aquino, Melissa, Kini, Annapoorna, Kapadia, Samir, Weiss, Sandra, Strauss, Craig, Muhlestein, J. Brent, Toma, Catalin, Rao, Sunil V., DeFranco, Anthony, Poddar, Kanhaiya L., Chandrasekhar, Jaya, Weintraub, William, Henry, Timothy D., Bansilal, Sameer, Baker, Brian A., Marrett, Elizabeth, Keller, Stuart, Effron, Mark, Pocock, Stuart and Mehran, Roxana (2017). Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. American Heart Journal, 188, 73-81. doi: 10.1016/j.ahj.2017.02.013

Impact of proton pump inhibitor use on the comparative effectiveness and safety of prasugrel versus clopidogrel: Insights from the treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (translate-acs) study

Jackson, Larry R., Peterson, Eric D., McCoy, Lisa A., Ju, Christine, Zettler, Marjorie, Baker, Brian A., Messenger, John C., Faries, Douglas E., Effron, Mark B., Cohen, David J. and Wang, Tracy Y. (2016). Impact of proton pump inhibitor use on the comparative effectiveness and safety of prasugrel versus clopidogrel: Insights from the treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (translate-acs) study. Journal of the American Heart Association, 5 (10) e003824, 1-11. doi: 10.1161/JAHA.116.003824

Comparing inverse probability of treatment weighting and instrumental variable methods for the evaluation of adenosine diphosphate receptor inhibitors after percutaneous coronary intervention

Federspiel, Jerome J., Anstrom, Kevin J., Xian, Ying, McCoy, Lisa A., Effron, Mark B., Faries, Douglas E., Zettler, Marjorie, Mauri, Laura, Yeh, Robert W., Peterson, Eric D., Wang, Tracy Y. and for the Treatment With Adenosine Diphosphate Receptor Inhibitors–Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Investigators (2016). Comparing inverse probability of treatment weighting and instrumental variable methods for the evaluation of adenosine diphosphate receptor inhibitors after percutaneous coronary intervention. JAMA Cardiology, 1 (6), 655-665. doi: 10.1001/jamacardio.2016.1783

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study

Vora, Amit N., Peterson, Eric D., Mccoy, Lisa A., Effron, Mark B., Anstrom, Kevin J., Faries, Douglas E., Zettler, Marjorie E., Fonarow, Gregg C., Baker, Brian A., Stone, Gregg W. and Wang, Tracy Y. (2016). Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. Journal of the American Heart Association, 5 (9) e003946. doi: 10.1161/JAHA.116.003946

Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study : Sex-Related Differences in Young Patients Undergoing PCI

Chandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Faggioni, Michela, Aquino, Melissa, Kini, Annapoorna, Weintraub, William, Rao, Sunil, Kapadia, Samir, Weiss, Sandra, Strauss, Craig, Toma, Catalin, Muhlestein, Brent, DeFranco, Anthony, Effron, Mark, Keller, Stuart, Baker, Brian, Pocock, Stuart, Henry, Timothy and Mehran, Roxana (2016). Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study : Sex-Related Differences in Young Patients Undergoing PCI. Catheterization and Cardiovascular Interventions, 89 (4), 629-637. doi: 10.1002/ccd.26606

Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel

Bae, Jay P., Faries, Douglas E., Ernst, Frank R., Lipkin, Craig, Zhao, Zhenxiang, Moretz, Chad, Lieu, Hsiao D. and Effron, Mark B. (2016). Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. American Journal of Health-System Pharmacy, 73 (6), 395-403. doi: 10.2146/ajhp150065

Unplanned inpatient and observation rehospitalizations after acute myocardial infarction: Insights from the treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study

Hess, Connie N., Wang, Tracy Y., McCoy, Lisa A., Messenger, John C., Effron, Mark B., Zettler, Marjorie E., Henry, Timothy D., Peterson, Eric D. and Fonarow, Gregg C. (2016). Unplanned inpatient and observation rehospitalizations after acute myocardial infarction: Insights from the treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circulation, 133 (5), 493-501. doi: 10.1161/CIRCULATIONAHA.115.017001

Impact of bleeding on quality of life in patients on DAPT: insights from TRANSLATE-ACS

Amin, Amit P., Wang, Tracy Y., McCoy, Lisa, Bach, Richard G., Effron, Mark B., Peterson, Eric D. and Cohen, David J. (2016). Impact of bleeding on quality of life in patients on DAPT: insights from TRANSLATE-ACS. Journal of the American College of Cardiology, 67 (1), 59-65. doi: 10.1016/j.jacc.2015.10.034

How reliable are patient-reported rehospitalizations?: implications for the design of future practical clinical studies

Krishnamoorthy, Arun, Peterson, Eric D., Knight, J. David, Anstrom, Kevin J., Effron, Mark B., Zettler, Marjorie E., Davidson-Ray, Linda, Baker, Brian A., McCollam, Patrick L., Mark, Daniel B. and Wang, Tracy Y. (2016). How reliable are patient-reported rehospitalizations?: implications for the design of future practical clinical studies. Journal of the American Heart Association, 5 (1) e002695. doi: 10.1161/JAHA.115.002695

Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel: from the TRANSLATE-ACS study

Jackson, Larry R., Ju, Christine, Zettler, Marjorie, Messenger, John C., Cohen, David J., Stone, Gregg W., Baker, Brian A., Effron, Mark, Peterson, Eric D. and Wang, Tracy Y. (2015). Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel: from the TRANSLATE-ACS study. Jacc-Cardiovascular Interventions, 8 (14), 1880-1889. doi: 10.1016/j.jcin.2015.08.018

“Real-World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States : Prasugrel vs. Ticagrelor in a “Real World” Study

Larmore, Cynthia, Effron, Mark B., Molife, Cliff, DeKoven, Mitch, Zhu, Yajun, Lu, Jingsong, Karkare, Swapna, Lieu, Hsiao D., Lee, Won Chan and Vetrovec, George W. (2015). “Real-World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States : Prasugrel vs. Ticagrelor in a “Real World” Study. Catheterization and Cardiovascular Interventions, 88 (4), 535-544. doi: 10.1002/ccd.26279

Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor

Molife, Cliff, Frech-Tamas, Feride, DeKoven, Mitch, Effron, Mark B., Karkare, Swapna, Zhu, Yajun, Larmore, Cynthia, Lu, Jingsong, McCollam, Patrick, Marrett, Elizabeth and Vetrovec, George W. (2015). Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. Journal of Medical Economics, 18 (11), 898-908. doi: 10.3111/13696998.2015.1060979

Contemporary use of platelet function and pharmacogenomic testingamongpatients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States

Wang, Tracy Y., Henry, Timothy D., Mccoy, Lisa A., Berger, Peter B., Cohen, David J., Effron, Mark B., Zettler, Marjorie, Baker, Brian A., Messenger, John C. and Peterson, Eric D. (2015). Contemporary use of platelet function and pharmacogenomic testingamongpatients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. American Heart Journal, 170 (4), 706-714. doi: 10.1016/j.ahj.2015.06.021

One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel

Simeone, Jason C., Molife, Cliff, Marrett, Elizabeth, Frech-Tamas, Feride, Effron, Mark B., Nordstrom, Beth L., Zhu, Yajun E., Keller, Stuart, Murphy, Brian R., Nair, Kavita V., Vetrovec, George W., Page, Robert L. and McCollam, Patrick L. (2015). One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. American Journal of Cardiovascular Drugs, 15 (5), 337-350. doi: 10.1007/s40256-015-0147-y

Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study

Xian, Ying, Wang, Tracy Y., McCoy, Lisa A., Effron, Mark B., Henry, Timothy D., Bach, Richard G., Zettler, Marjorie E., Baker, Brian A., Fonarow, Gregg C. and Peterson, Eric D. (2015). Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circulation, 132 (3), 174-181. doi: 10.1161/CIRCULATIONAHA.114.014992

Early medication nonadherence after acute myocardial infarction insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study

Mathews, Robin, Peterson, Eric D., Honeycutt, Emily, Chin, Chee Tang, Effron, Mark B., Zettler, Marjorie, Fonarow, Gregg C., Henry, Timothy D. and Wang, Tracy Y. (2015). Early medication nonadherence after acute myocardial infarction insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circulation-Cardiovascular Quality and Outcomes, 8 (4), 347-356. doi: 10.1161/CIRCOUTCOMES.114.001223

Cluster-randomized clinical trial examining the impact of platelet function testing on practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study

Wang, Tracy Y., Henry, Timothy D., Effron, Mark B., Honeycutt, Emily, Hess, Connie N., Zettler, Marjorie E., Cohen, David J., Baker, Brian A., Berger, Peter B., Anstrom, Kevin J., Angiolillo, Dominick J. and Peterson, Eric D. (2015). Cluster-randomized clinical trial examining the impact of platelet function testing on practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. Circulation-Cardiovascular Interventions, 8 (6). doi: 10.1161/CIRCINTERVENTIONS.114.001712

Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States

Bae, Jay P., Faries, Douglas E., Ernst, Frank R., Lipkin, Craig, Zhao, Zhenxiang, Moretz, Chad, Lieu, Hsiao D. and Effron, Mark B. (2014). Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Current Medical Research and Opinion, 30 (11), 2207-2216. doi: 10.1185/03007995.2014.941055

Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients High on-treatment platelet reactivity analysis of the TRIPLET trial

Diodati, Jean G., Saucedo, Jorge F., Cardillo, Tracy E., Jakubowski, Joseph A., Henneges, Carsten, Effron, Mark B., Lipkin, Fred R., Walker, Joseph R., Duvvuru, Suman, Sundseth, Scott S., Fisher, Harold N. and Angiolillo, Dominick J. (2014). Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients High on-treatment platelet reactivity analysis of the TRIPLET trial. Thrombosis and Haemostasis, 112 (2), 311-322. doi: 10.1160/TH13-09-0747

Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention

Wang, Tracy Y., Mccoy, Lisa, Henry, Timothy D., Effron, Mark B., Messenger, John C., Cohen, David J., Mark, Daniel B., Stone, Gregg W., Zettler, Marjorie, Singh, Mandeep, Fonarow, Gregg C. and Peterson, Eric D. (2014). Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. Journal of the American College of Cardiology, 63 (16), 1700-1702. doi: 10.1016/j.jacc.2013.12.012

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease Results of the SWAP-2 Study (Switching Anti Platelet-2)

Angiolillo, Dominick J., Curzen, Nicholas, Gurbel, Paul, Vaitkus, Paul, Lipkin, Fred, Li, Wei, Jakubowski, Joseph A., Zettler, Marjorie, Effron, Mark B. and Trenk, Dietmar (2014). Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease Results of the SWAP-2 Study (Switching Anti Platelet-2). Journal of the American College of Cardiology, 63 (15), 1500-1509. doi: 10.1016/j.jacc.2013.11.032

Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial

Diodati, Jean G., Saucedo, Jorge F., French, John K., Fung, Anthony Y., Cardillo, Tracy E., Henneges, Carsten, Effron, Mark B., Fisher, Harold N. and Angiolillo, Dominick J. (2013). Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circulation-Cardiovascular Interventions, 6 (5), 567-574. doi: 10.1161/CIRCINTERVENTIONS.112.000063

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

Braun, Oscar O., Angiolillo, Dominick J., Ferreiro, Jose L., Jakubowski, Joseph A., Winters, Kenneth J., Effron, Mark B., Duvvuru, Suman, Costigan, Timothy M., Sundseth, Scott S., Walker, Joseph R., Saucedo, Jorge F., Kleiman, Neal S. and Varenhorst, Christoph (2013). Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and Haemostasis, 110 (6), 1223-1231. doi: 10.1160/TH13-03-0263

Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention

Nordstrom, Beth L., Simeone, Jason C., Zhao, Zhenxiang, Molife, Cliff, McCollam, Patrick L., Ye, Xin and Effron, Mark B. (2013). Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention. American Journal of Cardiovascular Drugs, 13 (4), 263-271. doi: 10.1007/s40256-013-0028-1

TransRadial Education And Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium

Hess, Connie N., Rao, Sunil V., Kong, David F., Miller, Julie M., Anstrom, Kevin J., Bertrand, Olivier F., Collet, Jean-Philippe, Effron, Mark B., Eloff, Benjamin C., Fadiran, Emmanuel O., Farb, Andrew, Gilchrist, Ian C., Holmes, David R., Jacobs, Alice K., Kaul, Prashant, Newby, L. Kristin, Rutledge, David R., Tavris, Dale R., Tsai, Thomas T., White, Roseann M., Peterson, Eric D. and Krucoff, Mitchell W. (2013). TransRadial Education And Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium. American Heart Journal, 165 (3), 344-353.e1. doi: 10.1016/j.ahj.2012.09.008

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study

Saucedo, Jorge F., Angiolillo, Dominick J., DeRaad, Roger, Frelinger, Andrew L., Gurbel, Paul A., Costigan, Timothy M., Jakubowski, Joseph A., Ojeh, Clement K., Duvvuru, Suman and Effron, Mark B. (2013). Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thrombosis and Haemostasis, 109 (2), 347-355. doi: 10.1160/TH12-06-0378

Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research

Chin, Chee Tang, Wang, Tracy Y., Anstrom, Kevin J., Zhu, Baojin, Maa, Jen-Fue, Messenger, John C., Ryan, Kelley A., Davidson-Ray, Linda, Zettler, Marjorie, Effron, Mark B., Mark, Daniel B. and Peterson, Eric D. (2011). Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. American Heart Journal, 162 (5), 844-851. doi: 10.1016/j.ahj.2011.08.021

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

Angiolillo, Dominick J., JoseBadimon, Juan, Saucedo, Jorge F., Frelinger, Andrew L., Michelson, Alan D., Jakubowski, Joseph A., Zhu, Baojin, Ojeh, Clement K., Baker, Brian A. and Effron, Mark B. (2011). A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European Heart Journal, 32 (7), 838-846. doi: 10.1093/eurheartj/ehq494

The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data

Zhu, Baojin, Effron, Mark B., Kulkarni, Pandurang M., Li, Ying G., Jakubowski, Joseph A., Miller, Debra L., Baker, Brian A., Luo, Junxiang, Small, David S. and Winters, Kenneth J. (2011). The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. Journal of Cardiovascular Pharmacology, 57 (3), 317-324. doi: 10.1097/FJC.0b013e3182073dfb

Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study

Angiolillo, Dominick J., Saucedo, Jorge F., DeRaad, Roger, Frelinger, Andrew L., Gurbel, Paul A., Costigan, Timothy M., Jakubowski, Joseph A., Ojeh, Clement K. and Effron, Mark B. (2010). Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study. Journal of the American College of Cardiology, 56 (13), 1017-1023. doi: 10.1016/j.jacc.2010.02.072

Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention A Formal Prospective Nonrandomized Substudy of the FINESSE Trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)

Montalescot, Gilles, Ellis, Stephen G., de Belder, Mark A., Janssens, Luc, Katz, Olivier, Pluta, Wladyslaw, Ecollan, Patrick, Tendera, Michal, van Boven, Ad J., Widimsky, Petr, Andersen, Henning R., Betriu, Amadeo, Armstrong, Paul, Brodie, Bruce R., Herrmann, Howard C., Neumann, Franz-Josef, Effron, Mark B., Lu, Jiandong, Barnathan, Elliot S. and Topol, Eric J. (2010). Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention A Formal Prospective Nonrandomized Substudy of the FINESSE Trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). Jacc-Cardiovascular Interventions, 3 (2), 203-212. doi: 10.1016/j.jcin.2009.11.012

Response to Letter Regarding Article "Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in the Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors"

Collins, Peter, Mosca, Lori, Geiger, Mary Jane, Amewou-Atisso, Messan G., Effron, Mark B., Dowsett, Sherie, Grady, Deborah, Kornitzer, Marcel, Barrett-Connor, Elizabeth and Wenger, Nanette K. (2009). Response to Letter Regarding Article "Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in the Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors". Circulation, 120 (17), E148-E148. doi: 10.1161/CIRCULATIONAHA.109.876920

1-Year Survival in a Randomized Trial of Facilitated Reperfusion Results From the FINESSE (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events) Trial

Ellis, Stephen G., Tendera, Michal, de Belder, Mark A., van Boven, Ad J., Widimsky, Petr, Andersen, Henning R., Betriu, Amadeo, Savonitto, Stefano, Adamus, Jerzy, Peruga, Jan Z., Hamankiewicz, Maciej, Pluta, Waladyslaw, Oldroyd, Keith, Ecollan, Patrick, Janssens, Luc, Armstrong, Paul, Brodie, Bruce R., Herrmann, Howard C., Montalescot, Gilles, Neumann, Franz-Josef, Effron, Mark B., Bamathan, Elliot S. and Topol, Eric J. (2009). 1-Year Survival in a Randomized Trial of Facilitated Reperfusion Results From the FINESSE (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events) Trial. Jacc-Cardiovascular Interventions, 2 (10), 909-916. doi: 10.1016/j.jcin.2009.07.009

Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals

Herrmann, Howard C., Lu, Jiandong, Brodie, Bruce R., Armstrong, Paul W., Montalescot, Gilles, Betriu, Amadeo, Neuman, Franz-Joseph, Effron, Mark B., Barnathan, Elliot S., Topol, Eric J. and Ellis, Stephen G. (2009). Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals. Jacc-Cardiovascular Interventions, 2 (10), 917-924. doi: 10.1016/j.jcin.2009.06.018

Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial Results of Subgroup Analyses by Age and Other Factors

Collins, Peter, Mosca, Lori, Geiger, Mary Jane, Grady, Deborah, Kornitzer, Marcel, Amewou-Atisso, Messan G., Effron, Mark B., Dowsett, Sherie A., Barrett-Connor, Elizabeth and Wenger, Nanette K. (2009). Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial Results of Subgroup Analyses by Age and Other Factors. Circulation, 119 (7), 922-930. doi: 10.1161/CIRCULATIONAHA.108.817577

Treating Patients With 'Wake-Up' Stroke The Experience of the AbESTT-II Trial

Adams, Harold P., Leira, Enrique C., Torner, James C., Barnathan, Elliot, Padgett, Lakshmi, Effron, Mark B. and Hacke, Werner (2008). Treating Patients With 'Wake-Up' Stroke The Experience of the AbESTT-II Trial. Stroke, 39 (12), 3277-3282. doi: 10.1161/STROKEAHA.107.508853

Antibiotic overuse: The influence of social norms

Buchman, Timothy G., Dushoff, Jonathan, Effron, Mark B., Ehrlich, Paul R., Fitzpatrick, Susan, Laxminarayan, Ramanan, Levin, Bruce, Levin, Simon A., Lipsitch, Marc, Malani, Anup, Nemeroff, Carol, Otto, Sarah P., Patel, Vimla L. and Solomkin, Joseph S. (2008). Antibiotic overuse: The influence of social norms. Journal of the American College of Surgeons, 207 (2), 265-275. doi: 10.1016/j.jamcollsurg.2008.02.035

Facilitated PCI in patients with ST-elevation myocardial infarction

Ellis, Stephen G., Tendera, Michal, de Belder, Mark A., van Boven, Ad J., Widimsky, Petr, Janssens, Luc, Andersen, H. R., Betriu, Amadeo, Savonitto, Stefano, Adamus, Jerzy, Peruga, Jan Z., Kosmider, Maciej, Katz, Olivier, Neunteufl, Thomas, Jorgova, Julia, Dorobantu, Maria, Grinfeld, Liliana, Armstrong, Paul, Brodie, Bruce R., Herrmann, Howard C., Montalescot, Gilles, Neumann, Franz-Josef, Effron, Mark B., Barnathan, Elliot S. and Topol, Eric J. (2008). Facilitated PCI in patients with ST-elevation myocardial infarction. New England Journal of Medicine, 358 (21), 2205-2217. doi: 10.1056/NEJMoa0706816

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial - Abciximab in emergency treatment of stroke trial (AbESTT-II)

Adams, Harold P., Effron, Mark B., Torner, James, Davalos, Antoni, Frayne, Judith, Teal, Philip, Leclerc, Jacques, Oemar, Barry, Padgett, Lakshmi, Barnathan, Elliot S. and Hacke, Werner (2008). Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial - Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke, 39 (1), 87-99. doi: 10.1161/STROKEAHA.106.476648

Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction

Nikolsky, E, Sadeghi, HM, Effron, MB, Mehran, R, Lansky, AJ, Na, YB, Cox, DA, Garcia, E, Tcheng, JE, Griffin, JJ, Stuckey, TD, Turco, M, Carroll, JD, Grines, CL and Stone, GW (2005). Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. American Journal of Cardiology, 96 (4), 474-481. doi: 10.1016/j.amjcard.2005.04.005

Final results of the ReoPro Readministration Registry

Dery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, K, Little, T, George, BS, Sane, DC, Cines, DB, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2004). Final results of the ReoPro Readministration Registry. American Journal of Cardiology, 93 (8), 979-984. doi: 10.1016/j.amjcard.2003.12.051

Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial)

Kandzari, DE, Tcheng, JE, Cohen, DJ, Bakhai, A, Grines, CL, Cox, DA, Effron, M, Stuckey, T, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial). American Journal of Cardiology, 92 (7), 779-784. doi: 10.1016/S0002-9149(03)00882-8

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

Tcheng, JE, Kandzari, DE, Grines, CL, Cox, DA, Effron, MB, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, T, Turco, M, Fahy, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation, 108 (11), 1316-1323. doi: 10.1161/01.CIR.0000087601.45803.86

Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions

Kleiman, NS, Grazeiadei, N, Maresh, K, Taylor, RJ, Frederick, B, Lance, ET, Effron, MB, Jordan, RE and Mascelli, MA (2000). Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. American Heart Journal, 140 (3), 492-501. doi: 10.1067/mhj.2000.109220

Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials

Lincoff, AM, LeNarz, LA, Despotis, GJ, Smith, PK, Booth, JE, Raymond, RE, Sapp, SK, Cabot, CF, Tcheng, JE, Califf, RM, Effron, MB and Topol, EJ (2000). Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials. Annals of Thoracic Surgery, 70 (2), 516-526. doi: 10.1016/S0003-4975(00)01343-6

Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty

Fredrickson, BJ, Turner, NA, Kleiman, NS, Graziadei, N, Maresh, K, Mascelli, MA, Effron, MB and McIntire, LV (2000). Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation, 101 (10), 1122-1129. doi: 10.1161/01.CIR.101.10.1122

Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients

Mak, KH, Effron, MB and Moliterno, DJ (2000). Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs & Aging, 16 (3), 179-187. doi: 10.2165/00002512-200016030-00003

Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study

Makkar, R, Goff, B, Eigler, N, Sebastian, M, Fischell, T, Barr, L, D'Haem, C, Shah, PK, Effron, MB and Litvack, F (1999). Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. Catheterization and Cardiovascular Interventions, 48 (4), 430-434. doi: 10.1002/(SICI)1522-726X(199912)48:4<430::AID-CCD20>3.0.CO;2-G

Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty

Brener, SJ, Barr, LA, Burchenal, JEB, Wolski, KE, Effron, MB and Topol, EJ (1999). Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. American Journal of Cardiology, 84 (6), 728-+. doi: 10.1016/S0002-9149(99)00421-X

Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)

Ellis, SG, Effron, MB, Gold, HK, Leon, MB, Popma, JJ, Serruys, PWJC, Colombo, A, Cohen, N, Juran, N, Werner, W, Heuser, RR, Spooner, S, Rihal, CS, Fox, R, Leon, MB, Brennan, J, Ricci, D, Fox, R, Teirstein, PS, Norman, S, Morris, N, Zidar, J and Rund, M (1999). Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation, 100 (8), 799-806.

Readministration of abciximab: Interim report of the ReoPro Readministration Registry

Tcheng, JE, Kereiakes, DJ, Braden, GA, Jordan, RE, Mascelli, MA, Langrall, MA and Effron, MB (1999). Readministration of abciximab: Interim report of the ReoPro Readministration Registry. American Heart Journal, 138 (1), S33-S38. doi: 10.1053/hj.1999.v138.99236

Rapport? Reply

Brener, SJ, Topol, EJ, Moliterno, DJ, Barr, LA, Burchenal, JEB, Katz, S, George, BS, Jones, AA, Cohen, ED, Gainey, PC, White, HJ, Cheek, HB, Moses, JW and Effron, MB (1999). Rapport? Reply. Circulation, 99 (25), 3324-3324.

Abciximab and alveolar hemorrhage - reply

Cohen, SA and Effron, MB (1998). Abciximab and alveolar hemorrhage - reply. New England Journal of Medicine, 339 (25), 1862-1863.

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction

Brener, SJ, Barr, LA, Burchenal, JEB, Katz, S, George, BS, Jones, AA, Cohen, ED, Gainey, PC, White, HJ, Cheek, HB, Moses, JW, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation, 98 (8), 734-741. doi: 10.1161/01.CIR.98.8.734

Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction

Fuster, , Califf, RM, Chesebro, JH, Cohen, M, Comp, PC, Gheorghiade, M, Hall, J, Halperin, J, Khan, S, Kopecky, S, Langer, A, Molk, B, Moss, A, OConnor, CM, OGara, PT, Raskob, E, Sutton, J, Braunwald, E, Bell, WR, Furberg, C, Rapaport, E, DeMets, D, Goldstein, S, Richardson, D, Hillis, D, Bonow, R, Kistler, JP, Mohr, JP, Sherman, D ... Smith, C (1997). Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet, 350 (9075), 389-396.

The effect of digoxin on mortality and morbidity in patients with heart failure

Perry, G, Brown, E, Thornton, R, Shiva, T, Hubbard, J, Reddy, KR, Doherty, JE, Cardello, FP, Fast, A, Radford, MJ, Folger, JS, Bhaskar, G, Zoble, RG, Sridharan, , Sridharan, MR, Loungani, RR, Gheorghiade, M, Hsieh, A, Tommaso, C, Mansuri, M, Guess, MA, Akhtar, S, Wagner, S, Hagan, K, McIntyre, KM, Ruble, P, Moten, M, Riley, A, Pierpont, G ... Singh, BN (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine, 336 (8), 525-533.

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina - A randomized multicenter trial

Schulman, SP, GoldschmidtClermont, PJ, Topol, EJ, Califf, RM, Navetta, FI, Willerson, JT, Chandra, NC, Guerci, AD, Ferguson, JJ, Harrington, RA, Lincoff, AM, Yakubov, SJ, Bray, PF, Bahr, RD, Wolfe, CL, Yock, PG, Anderson, HV, Nygaard, TW, Mason, SJ, Effron, MB, Fatterpacker, A, Raskin, S, Smith, J, Brashears, L, Gottdiener, P, duMee, C, Kitt, MM and Gerstenblith, G (1996). Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina - A randomized multicenter trial. Circulation, 94 (9), 2083-2089. doi: 10.1161/01.CIR.94.9.2083

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure

Abernathy, GT, Abrams, J, Akhtar, S, Albitar, , Amidi, M, Anand, IS, Arnold, JMO, Ashton, T, Aubrey, B, Auger, P, Babb, J, Baigrie, R, Baird, MG, Baitz, T, Barber, NC, Barbour, DJ, Barr, DM, Basu, AK, Baughman, KL, Beckham, , BekheitSaad, S, Berkson, DM, Bertoglio, M, Bessoudo, R, Beaudoin, J, Bhaskar, G, Binder, A, Bloomfield, D, Bodine, K ... Martinez, G (1996). Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials, 17 (1), 77-97.

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

Mindlen, F, Nordaby, R, Ruiz, M, Zavala, A, Guzman, L, Martinez, F, Diaz, RR, Mackey, C, Marino, M, Romero, G, Zapata, G, Cuneo, C, Kawamura, T, Coelho, O, Massayochi, O, Braga, J, Labrunie, A, Bodanese, L, Manenti, E, Vitola, D, Nicolau, J, Amodeo, C, Armaganijan, D, Bertolami, M, Caramelli, B, Carvalho, A, Cirenza, C, Fichino, M, Franken, R ... Kennedy, JW (1996). The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology, 12 (2), 127-137.

INCIDENCE, PREDICTORS AND IMPACT OF STROKE AFTER PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES: RESULTS FROM THE PROMETHEUS REGISTRY

Giustino, Gennaro, Baber, Usman, Sartori, Samantha, Aoi, Shunsuke, Aquino, Melissa, Chandrasekhar, Jaya, Weintraub, William, Rao, Sunil, Weiss, Sandra, Henry, Timothy, Kapadia, Samir, Poddar, Kanhaiya, DeFranco, Anthony, Muhlestein, J., Toma, Catalin, Effron, Mark, Keller, Stuart, Baker, Brian, Pocock, Stuart and Mehran, Roxana (2016). INCIDENCE, PREDICTORS AND IMPACT OF STROKE AFTER PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES: RESULTS FROM THE PROMETHEUS REGISTRY. 65th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC), Chicago Il, Apr 02-04, 2016. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(16)30049-3

USE OF CLOPIDOGREL VERSUS PRASUGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: FACTORS INFLUENCING REAL-WORLD THERAPEUTIC DECISION-MAKING

Salianski, Olga, Baber, Usman, Sartori, Samantha, Aquino, Melissa, Chandrasekhar, Jaya, Kini, Annapoorna, Rao, Sunil, Weintraub, William, Weiss, Sandra, Henry, Timothy, Kapadia, Samir, Poddar, Kanhaiya, DeFranco, Anthony, Muhlestein, J., Toma, Catalin, Effron, Mark, Keller, Stuart, Baker, Brian, Pocock, Stuart and Mehran, Roxana (2016). USE OF CLOPIDOGREL VERSUS PRASUGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: FACTORS INFLUENCING REAL-WORLD THERAPEUTIC DECISION-MAKING. 65th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC), Chicago Il, Apr 02-04, 2016. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(16)30185-1

Clinical Outcomes Using Prasugrel or Ticagrelor Based On Physician Treatment Decisions In Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Comparative Results Using Propensity Analysis Of A Payer Database

Effron, Mark B., Nair, Kavita V., Molife, Cliff, Keller, Stuart Y., Page, Robert L., Simeone, Jason, Murphy, Brian, Nordstrom, Beth L., Zhu, Yajun, McCollam, Patrick L. and Vetrovec, George W. (2015). Clinical Outcomes Using Prasugrel or Ticagrelor Based On Physician Treatment Decisions In Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Comparative Results Using Propensity Analysis Of A Payer Database. 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), San Francisco Ca, Oct 11-15, 2015. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2015.08.184

Effect of prasugrel versus clopidogrel in ACS patients with high or low BMI undergoing PCI: Results from the PROMETHEUS Study

Chandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Aquino, Melissa, Strauss, Craig E., Muhlestein, Joseph B., Weiss, Sandra, Effron, Mark B., Keller, Stuart Y., Baker, Brian A., Chao, Jennifer, Rao, Sunil, Kapadia, Samir, Poddar, Kanhaiya L., DeFranco, Anthony, Kini, Annapoorna, Weintraub, William, Henry, Timothy D. and Mehran, Roxana (2015). Effect of prasugrel versus clopidogrel in ACS patients with high or low BMI undergoing PCI: Results from the PROMETHEUS Study. 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), San Francisco Ca, Oct 11-15, 2015. NEW YORK: ELSEVIER SCIENCE INC.

Impact of prasugrel versus clopidogrel in ACS patients undergoing PCI with short or long stents: Results from the PROMETHEUS Study

Chandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Aquino, Melissa, Henry, Timothy D., Kini, Annapoorna, Kapadia, Samir, Rao, Sunil, Weiss, Sandra, Muhlestein, Joseph B., Poddar, Kanhaiya L., Baker, Brian A., Keller, Stuart Y., Effron, Mark B., Chao, Jennifer, Strauss, Craig E., DeFranco, Anthony, Weintraub, William and Mehran, Roxana (2015). Impact of prasugrel versus clopidogrel in ACS patients undergoing PCI with short or long stents: Results from the PROMETHEUS Study. 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), San Francisco Ca, Oct 11-15, 2015. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2015.08.234

Impact of prasugrel versus clopidogrel in smokers and non-smokers undergoing PCI for ACS: Results from the PROMETHEUS Study

Chandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Aquino, Melissa, DeFranco, Anthony, Muhlestein, Joseph B., Weiss, Sandra, Henry, Timothy D., Effron, Mark B., Strauss, Craig E., Keller, Stuart Y., Baker, Brian A., Weintraub, William, Chao, Jennifer, Poddar, Kanhaiya L., Rao, Sunil, Kapadia, Samir, Kini, Annapoorna and Mehran, Roxana (2015). Impact of prasugrel versus clopidogrel in smokers and non-smokers undergoing PCI for ACS: Results from the PROMETHEUS Study. 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), San Francisco Ca, Oct 11-15, 2015. NEW YORK: ELSEVIER SCIENCE INC.

Temporal Associations Between Myocardial Infarction, Major Bleeding and Mortality Risk in ACS Patients Undergoing PCI: Insights from the PROMETHEUS Cohort

Baber, Usman, Chao, Jennifer, Chandrasekhar, Jaya, Sartori, Samantha, Aquino, Melissa, Kini, Annapoorna, Rao, Sunil, Weintraub, William, Weiss, Sandra, Strauss, Craig E., Kapadia, Samir, Henry, Timothy D., DeFranco, Anthony, Muhlestein, Joseph B., Toma, Catalin, Pocock, Stuart J., Keller, Stuart Y., Effron, Mark B., Baker, Brian A. and Mehran, Roxana (2015). Temporal Associations Between Myocardial Infarction, Major Bleeding and Mortality Risk in ACS Patients Undergoing PCI: Insights from the PROMETHEUS Cohort. 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), San Francisco Ca, Oct 11-15, 2015. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2015.08.503

IMPACT OF PROTON PUMP INHIBITOR USE ON THE COMPARATIVE SAFETY AND EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL: INSIGHTS FROM TRANSLATE-ACS

Jackson, Larry R., Peterson, Eric, McCoy, Lisa, Ju, Christine, Zettler, Marjorie, Baker, Brian, Messenger, John, Faries, Douglas, Effron, Mark, Cohen, David and Wang, Tracy (2015). IMPACT OF PROTON PUMP INHIBITOR USE ON THE COMPARATIVE SAFETY AND EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL: INSIGHTS FROM TRANSLATE-ACS. Scientific Session of the American-College-of-Cardiology (ACC), San Diego Ca, Mar 14-16, 2015. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(15)60225-X

SELECTION OF PRASUGREL VERSUS CLOPIDOGREL AMONG MYOCARDIAL INFARCTION PATIENTS WITH HIGH VERSUS LOW PREDICTED MORTALITY AND BLEEDING RISKS: INSIGHTS FROM TRANSLATE-ACS

Vora, Amit, Peterson, Eric, McCoy, Lisa, Effron, Mark, Anstrom, Kevin, Faries, Douglas, Zettler, Marjorie, Fonarow, Gregg, Baker, Brian, Stone, Gregg and Wang, Tracy (2015). SELECTION OF PRASUGREL VERSUS CLOPIDOGREL AMONG MYOCARDIAL INFARCTION PATIENTS WITH HIGH VERSUS LOW PREDICTED MORTALITY AND BLEEDING RISKS: INSIGHTS FROM TRANSLATE-ACS. Scientific Session of the American-College-of-Cardiology (ACC), San Diego Ca, Mar 14-16, 2015. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(15)60107-3

Safety and Effectiveness of Prasugrel vs. Clopidogrel in the Setting of Bivalirudin vs. Heparin Use: 30-day Results from TRANSLATE-ACS

Henry, Timothy D., Peterson, Eric, Cohen, David, Ju, Christine, Stone, Gregg W., Messenger, John C., Fonarow, Gregg C., Effron, Mark B., Baker, Brian A., Zettler, Marjorie and Wang, Tracy Y. (2014). Safety and Effectiveness of Prasugrel vs. Clopidogrel in the Setting of Bivalirudin vs. Heparin Use: 30-day Results from TRANSLATE-ACS. 26th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), Washington Dc, Sep 13-17, 2014. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2014.07.548

DIFFERENTIAL USE BETWEEN PRASUGREL AND TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN ROUTINE PRACTICE

Effron, Mark B., Molife, Cliff, Karkare, Swapna, Larmore, Cynthia, Zhu, Yajun, Lee, Won Chan, Frech-Tamas, Feride, Lieu, Hsiao and DeKoven, Mitch (2014). DIFFERENTIAL USE BETWEEN PRASUGREL AND TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN ROUTINE PRACTICE. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(14)60225-4

EFFICACY AND SAFETY OF PRETREATMENT AONG CONTEMPORARY ACUTE MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY

Effron, Mark B., Wang, Tracy, Fonarow, Gregg, Henry, Timothy, Zettler, Marjorie, Baker, Brian, McCoy, Lisa and Peterson, Eric (2014). EFFICACY AND SAFETY OF PRETREATMENT AONG CONTEMPORARY ACUTE MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(14)60101-7

TRIPLE THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: A COMPARISON OF CLOPIDOGREL VERSUS PRASUGREL FROM THE TRANSLATE-ACS STUDY

Jackson, Larry R., Zettler, Marjorie, Peterson, Eric, Ju, Christine, Effron, Mark, Messenger, John, Cohen, David, Stone, Gregg and Wang, Tracy (2014). TRIPLE THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: A COMPARISON OF CLOPIDOGREL VERSUS PRASUGREL FROM THE TRANSLATE-ACS STUDY. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(14)60026-7

A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease: Results of the SWAP-2 Study

Anaiolillo, Dominick J., Curzen, Nicholas, Gurbel, Paul A., Vaitkus, Paul, Lipkin, Fred, Li, Wei, Jakubowski, Joseph A., Zettler, Marjorie, Effron, Mark B. and Trenk, Dietmar (2013). A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease: Results of the SWAP-2 Study. Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association, Dallas Tx, Nov 16-17, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: 30-Day Outcomes from the TRANSLATE-ACS Observational Study

Wang, Tracy Y., Zettler, Marjorie, Effron, Mark B., McCoy, Lisa, Anstrom, Kevin, Fonarow, Gregg C., Messenger, John C., Stone, Gregg, Cohen, David, Henry, Timothy D. and Peterson, Eric (2013). Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: 30-Day Outcomes from the TRANSLATE-ACS Observational Study. 25th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), San Francisco Ca, Oct 27-Nov 01, 2013. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2013.08.729

High On-Treatment Platelet Reactivity among Contemporary Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study

Bagai, Akshay, Peterson, Eric, Honeycutt, Emily, Effron, Mark B., Stone, Gregg, Henry, Timothy D., Cohen, David, Anstrom, Kevin and Wang, Tracy Y. (2013). High On-Treatment Platelet Reactivity among Contemporary Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study. 25th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT), San Francisco Ca, Oct 27-Nov 01, 2013. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2013.08.882

Contemporary use of platelet function and pharmacogenomic testing among acute myocardial infarction patients treated with PCI in the United States: insights from the TRANSLATE-ACS study

Wang, T. Y., Henry, T. D., Mccoy, L. A., Berger, P. B., Cohen, D. J., Effron, M. B., Zettler, M., Vaitkus, P. T., Messenger, J. C. and Peterson, E. D. (2013). Contemporary use of platelet function and pharmacogenomic testing among acute myocardial infarction patients treated with PCI in the United States: insights from the TRANSLATE-ACS study. Congress of the European-Society-of-Cardiology (ESC), Amsterdam Netherlands, Aug 31-Sep 04, 2013. OXFORD: OXFORD UNIV PRESS.

EARLY CESSATION OF ADP RECEPTOR INHIBITORS AMONG ACUTE MYOCARDIAL INFARCTION PATIENTS TREATED WITH PCI: INSIGHTS FROM THE TRANSLATE-ACS STUDY

Fosbol, Emil L., Peterson, Eric, Honeycutt, Emily, Zettler, Marjorie, Messenger, John, Waksman, Ron, Effron, Mark, Vaitkus, Paul, Cohen, David and Wang, Tracy (2013). EARLY CESSATION OF ADP RECEPTOR INHIBITORS AMONG ACUTE MYOCARDIAL INFARCTION PATIENTS TREATED WITH PCI: INSIGHTS FROM THE TRANSLATE-ACS STUDY. 62nd Annual Scientific Session of the American-College-of-Cardiology, San Francisco Ca, Mar 09-11, 2013. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(13)61592-2

THE ASSOCIATION OF DISCHARGE ASPIRIN DOSE AND OUTCOMES IN ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY

Xian, Ying, Wang, Tracy, Kaltenbach, Lisa, Effron, Mark, Henry, Timothy, Bach, Richard, Zettler, Marjorie, Vaitkus, Paul, Fonarow, Gregg and Peterson, Eric (2013). THE ASSOCIATION OF DISCHARGE ASPIRIN DOSE AND OUTCOMES IN ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY. 62nd Annual Scientific Session of the American-College-of-Cardiology, San Francisco Ca, Mar 09-11, 2013. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(13)60112-6

Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: A Report from TRANSLATE-ACS

Hess, Connie N., Wang, Tracy Y., Kaltenbach, Lisa, Honeycutt, Emily, Messenger, John C., Smith, William T., Zettler, Marjorie E., Effron, Mark B., Henry, Timothy D., Peterson, Eric D. and Fonarow, Gregg C. (2012). Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: A Report from TRANSLATE-ACS. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High on-Treatment Platelet Reactivity Analysis of the TRIPLET Trial

Diodati, Jean, Angiolillo, Dominick, Saucedo, Jorge, Cardillo, Tracy, Jakubowski, Joseph, Henneges, Carsten, Effron, Mark, Lipkin, Fred and Fisher, Harold (2012). Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High on-Treatment Platelet Reactivity Analysis of the TRIPLET Trial. Transcatheter Cardiovascular Therapeutics (TCT) Symposium, Miami Fl, Oct 22-26, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jacc.2012.08.764

TRANSFERRING FROM CLOPIDOGREL LOADING DOSE TO PRASUGREL LOADING DOSE IN ACUTE CORONARY SYNDROME PATIENTS: THE TRIPLET TRIAL

Diodati, J. G., Fung, A., Saucedo, J. F., Oguzhan, A., Gaxiola, E., Cardillo, T. E., Effron, M. B., Fisher, H. N., Henneges, C. and Angiolillo, D. J. (2012). TRANSFERRING FROM CLOPIDOGREL LOADING DOSE TO PRASUGREL LOADING DOSE IN ACUTE CORONARY SYNDROME PATIENTS: THE TRIPLET TRIAL. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.cjca.2012.07.655

CHARACTERISTICS OF PATIENTS TREATED WITH THIENOPYRIDINES FOLLOWING ACS-PCI

Nordstrom, B., Simeone, J. C., Zhao, Z., Molife, C., Mccollam, P. L., Ye, X. and Effron, M. B. (2012). CHARACTERISTICS OF PATIENTS TREATED WITH THIENOPYRIDINES FOLLOWING ACS-PCI. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jval.2012.03.721

MEDICATION ADHERENCE AND PERSISTENCE OF PRASUGREL INITIATORS POST ACS-PCI

Simeone, J. C., Nordstrom, B., Zhao, Z., Molife, C., Mccollam, P. L., Ye, X. and Effron, M. B. (2012). MEDICATION ADHERENCE AND PERSISTENCE OF PRASUGREL INITIATORS POST ACS-PCI. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jval.2012.03.047

MEDICATION NONADHERENCE AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY

Mathews, Robin, Peterson, Eric, Honeycutt, Emily, Chin, Chee Tang, Ryan, Kelley, Effron, Mark, Zettler, Marjorie, Rozek, Maurice, Henry, Timothy and Wang, Tracy (2012). MEDICATION NONADHERENCE AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY. 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC), Chicago Il, Mar 24-27, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(12)61815-4

Post-discharge Bleeding and Thienopyridine Discontinuation among AMI Patients Treated with PCI: Insights from the TRANSLATE-ACS Study

Wang, Tracy Y., Honeycutt, Emily, Henry, Timothy D., Effron, Mark B., Messenger, John C., Cohen, David J., Mark, Daniel B., Stone, Gregg W., Singh, Mandeep, Rozek, Maurice, Fonarow, Gregg C. and Peterson, Eric D. (2011). Post-discharge Bleeding and Thienopyridine Discontinuation among AMI Patients Treated with PCI: Insights from the TRANSLATE-ACS Study. 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium, San Francisco Ca, Nov 07-11, 2011. NEW YORK: ELSEVIER SCIENCE INC.

Lack of rebound in platelet reactivity following cessation of prasugrel or clopidogrel in type 2 diabetes mellitus patients with coronary artery disease: insights from OPTIMUS-3

Angiolillo, D. J., Jakubowski, J. A., Frelinger, M. U., Zafar, M. U., Saucedo, J. F., Michelson, A. D., Zhu, B., Ojeh, C. K., Baker, B. A. and Effron, M. B. (2010). Lack of rebound in platelet reactivity following cessation of prasugrel or clopidogrel in type 2 diabetes mellitus patients with coronary artery disease: insights from OPTIMUS-3. ESC Congress, Stockholm Sweden, Aug 28-Sep 01, 2010. OXFORD: OXFORD UNIV PRESS.

Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Angiolillo, Dominick J., Badimon, Juan, Saucedo, Jorge F., Frelinger, Andrew L., Michelson, Alan D., Jakubowski, Joseph A., Zhu, Baojin, Ojeh, Clement K., Baker, Brian and Effron, Mark B. (2009). Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3). 82nd Scientific Session of the American-Heart-Association, Orlando Fl, Nov 14-18, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) Study

Saucedo, Jorge F., Angiolillo, Dominick J., DeRaad, Roger, Frelinger, Andrew L., Gurbel, Paul A., Costigan, Timothy M., Jakubowski, Joseph A., Ojeh, Clement K. and Effron, Mark B. (2009). Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) Study. 82nd Scientific Session of the American-Heart-Association, Orlando Fl, Nov 14-18, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES

Zhu, B., McCollam, P. L., Bae, J. P., Ramaswamy, K., Johnston, J. A. and Effron, M. B. (2009). PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. doi: 10.1016/S1098-3015(10)74562-9

REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA

Mahoney, E. M., Wang, K., Bae, J. P., Zhu, B., Marciniak, M. D., Effron, M. B. and Cohen, D. J. (2009). REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. doi: 10.1016/S1098-3015(10)74653-2

COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS

Bae, J. P., Zhu, B., McCollam, P. L., Ramaswamy, K., Johnston, J. A., Cohen, D. J. and Effron, M. B. (2008). COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. doi: 10.1016/S1098-3015(10)66384-X

Benefit of Facilitated PCI in High Risk ST Elevation MI Patients Presenting to Non-PCI Hospitals

Herrmann, Howard C., Liu, Jiandong, Brodie, Bruce R., Armstrong, Paul W., Montalescot, Gilles, Betriu, Amadeo, Neumann, Franz-Josef, Effron, Mark B., Barnathan, Elliot S., Topol, Eric. J. and Ellis, Stephen G. (2008). Benefit of Facilitated PCI in High Risk ST Elevation MI Patients Presenting to Non-PCI Hospitals. 20th Annual Transcatheter Cardiovascular Therapeutics Conference, Washington Ca, Oct 12-17, 2008. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC.

One year follow up results of the FINESSE trial of facilitated PCI

Ellis, Stephen G., Tendera, Michael, De Belder, Mark A., van Boven, Ad J., Widimsky, Petr, Janssens, Luc, Andersen, H. R., Betriu, Amadeo, Savonitto, Stefano, Adamus, Jerzy, Peruga, Jan Z., Kosmider, Maciej, Katz, Olivier, Neunteufl, Thomas, Jorgova, Julia, Dorobantu, Maria, Grinfeld, Liliana, Armstrong, Paul, Brodie, Bruce, Herrmann, Howard C., Montalescot, Gilles, Neumann, Franz-Josef, Effron, Mark B., Barnathan, Elliot S. and Topol, Eric J. (2008). One year follow up results of the FINESSE trial of facilitated PCI. 57th Annual Scientific Session of the American-College-of-Cardiology, Chicago Il, Mar 29-Apr 01, 2008. NEW YORK: ELSEVIER SCIENCE INC.

The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial: Results of the formal low molecular weight heparin substudy

Montalescot, Gilles, De Belder, Marka A., Janssens, Luc, Andersen, H. R., Pluta, Wladyslaw, Katz, Olivier, Ecollan, Patrick, Sorensen, Vigholt E., Dawkins, Keith D., Miarka, Jacek, De Belder, Adam, Lederballe, Ole, Adgey, Jennifer, Effron, Mark B., Barnathan, Elliot S. and Ellis, Stephen G. (2007). The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial: Results of the formal low molecular weight heparin substudy. 19th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington Dc, Oct 20-25, 2007. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC.

The FINESSE (Facilitated intervention with enhanced reperfusion speed to stop events) trial: Results of the formal low molecular weight heparin substudy

Montalescot, Gilles, Ellis, Stephen G., de Belder, Mark A., Janssens, Luc, Andersen, H. R., Pluta, Wladyslaw, Katz, Olivier, Ecollan, Patrick, Sorensen, Vigholt E., Dawkins, Keith D., Miarka, Jacek, de Belder, Adam, Lederballe, Ole, Adgey, Jennifer, Effron, Mark B. and Barnathan, Elliot S. (2007). The FINESSE (Facilitated intervention with enhanced reperfusion speed to stop events) trial: Results of the formal low molecular weight heparin substudy. 19th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington Dc, Oct 20-25, 2007. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC.

The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease

Patterson, D, Kloner, R, Effron, M, Emmick, J, Bedding, A, Warner, M, Mitchell, M, Braat, S and MacDonald, T (2005). The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Meeting of the International-Society-for-Sexual-and-Impotence-Research, Montreal Canada, Sep, 2002. OXFORD: BLACKWELL PUBLISHING. doi: 10.1111/j.1365-2125.2005.02479.x

Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration

Mann, HJ, Demmon, SL, Boelk, DA, Payne, CA, Effron, MB, Rajagopalan, N, Williams, MD, Beck, GM and Gopalrathnam, G (2004). Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. 38th Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists, New Orleans La, Dec 08-09, 2003. BETHESDA: AMER SOC HEALTH-SYSTEM PHARMACISTS. doi: 10.1093/ajhp/61.24.2664

Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patients

Rickert, T, Jay, S, Michael, C, Karen, S, Pamela, L, Effron, M, Linde-Zwirble, W and Zeckel, M (2004). Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patients. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.865S-a

Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational study

Karen, S, Lipsett, P, Effron, M, Rickert, T, Zeckel, M, Linde-Zwirble, W, Steingrub, J and Cheatham, M (2004). Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational study. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.724S-a

Abciximab readministration: Final results of the Reopro(fi) read ministration registry

Dery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, KF, Little, T, George, BS, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2003). Abciximab readministration: Final results of the Reopro(fi) read ministration registry. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC.

Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial

Kandzari, DE, Tcheng, JE, Grines, CL, Effron, M, Cox, DA, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, TD, Turco, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC.

Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial

Kandzari, DE, Tcheng, JE, Grines, CL, Cohen, DJ, Bakhai, A, Cox, DA, Stuckey, TD, Effron, M, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC.

Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial

Bakhai, A, Stone, GW, Murphy, SA, Githiora, L, Berezin, RH, Gedney, S, Hormel, P, Effron, M, Cox, DA, Tcheng, JE, Grines, CL and Cohen, DJ (2002). Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease

Patterson, D, MacDonald, TM, Effron, MB, Emmick, JT, Mitchell, MI and Kloner, RA (2002). Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data

Kennedy, JS, Bymaster, FP, Schuh, L, Calligaro, DO, Nomikos, G, Felder, CC, Bernauer, M, Kinon, BJ, Baker, RW, Hay, D, Roth, HJ, Dossenbach, M, Kaiser, C, Beasley, CM, Holcombe, JH, Effron, MB and Breier, A (2001). A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Symposium on Management of Psychoses in Older People, Barcelona Spain, Nov, 2000. W SUSSEX: JOHN WILEY & SONS LTD. doi: 10.1002/1099-1166(200112)16:1+<::AID-GPS571>3.0.CO;2-5

Abciximab readministration - Results of the ReoPro readministration registry

Tcheng, JE, Kereiakes, DJ, Lincoff, AM, George, BS, Kleiman, NS, Sane, DC, Cines, DB, Jordan, RE, Mascelli, MA, Langrall, MA, Damaraju, L, Schantz, A, Effron, MB and Braden, GA (2001). Abciximab readministration - Results of the ReoPro readministration registry. 71st Scientific Session of the American-Heart-Association, Dallas Tx, Nov 08-12, 1998. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1161/hc3301.094533

A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

Stone, GW, Grines, CL, Cox, DA, Garcia, E, Tcheng, JE, Stuckey, T, Carroll, J, Guagliumi, G, Rutherford, B, Johnson, G, Effron, M, Esente, P, Lansky, AJ and Griffin, J (2001). A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. NEW YORK: ELSEVIER SCIENCE INC.

Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial

Tcheng, JE, Effron, M, Grines, CL, Garcia, E, Cox, D, Stuckey, T, Carroll, J, Guagliumi, G, Rutherford, B, Lansky, AJ, Esente, P, Griffin, J and Stone, GW (2001). Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial. NEW YORK: ELSEVIER SCIENCE INC.

Abciximab improves outcomes in patients of all ages: Pooled analysis of 4 phase 3 trials

Effron, MB, Booth, J, Balog, C and Cabot, C (2000). Abciximab improves outcomes in patients of all ages: Pooled analysis of 4 phase 3 trials. NEW YORK: EXCERPTA MEDICA INC.

Comparison of GP IIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary interventions: a meta-analysis

Chadbourne, EB, Allen, IE, Luo, D, Gordon, MJ, Reid, P, Wilson, MG, Effron, MB, Perkins, LE, Jamal, HH and Ross, SD (2000). Comparison of GP IIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary interventions: a meta-analysis. LONDON: W B SAUNDERS CO LTD.

Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention

Marks, DS, Effron, MB, Mensah, GA, Fitzpatrick, SE, Tcheng, JE and Kereiakes, DF (1999). Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Abciximab accelerates the reperfusion process after primary angioplasty for acute myocardial infarction, without affecting enzymatic infarct size

Brener, SJ, Cannata, RK and Effron, MB (1998). Abciximab accelerates the reperfusion process after primary angioplasty for acute myocardial infarction, without affecting enzymatic infarct size. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Critical effect of timing of abciximab bolus relative to first balloon inflation in primary angioplasty. The RAPPORT trial

Brener, SJ, Cannata, RK, Effron, MB and Topol, NJ (1998). Critical effect of timing of abciximab bolus relative to first balloon inflation in primary angioplasty. The RAPPORT trial. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Provisional stenting improves outcome of primary angioplasty independently of the use of Abciximab. The RAPPORT trial

Brener, SJ, Barr, LA, Burcehnal, JEB, Katz, S and Effron, MB (1998). Provisional stenting improves outcome of primary angioplasty independently of the use of Abciximab. The RAPPORT trial. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3)

Tcheng, JE, Kereiakes, DJ, Braden, GA, Lincoff, AM, Mascelli, MA, Langrall, MA, Damaraju, LV, Schantz, AR, Barnathan, ES and Effron, MB (1998). Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study

Makkar, R, Goff, B, Eigler, N, Fischell, T, Barr, L, D'Haem, C, Shah, PK, Effron, MB and Litvack, F (1998). The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. NEW YORK: EXCERPTA MEDICA INC.

Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial

Barr, LA, Brener, SJ, Jones, AA, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84737-7

Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial

Brener, SJ, Barr, LA, Cohen, ED, White, HJ, Moliterno, DJ, Cheek, HB, Effron, MB and Topol, EJ (1998). Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83942-3

Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT

Brener, SJ, Ellis, SG, Burchenal, JEB, Katz, S, Effron, MB and Topol, EJ (1998). Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84709-2

Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3)

Tcheng, JE, Kereiakes, DJ, George, BS, Braden, G, Langrall, MA, Zelinger, D, Jordan, R and Effron, MB (1998). Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3). NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83944-7

Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting

Kleiman, NS, Graziadei, N, Lance, E, Maresh, K, Taylor, J, Higginbotham, J, Edwards, A, Effron, MB, Mascelli, MA and Jordan, RE (1998). Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84740-7

Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results

Ellis, SG, Serruys, PW, Popma, JJ, Teirstein, PS, Ricci, DR, Gold, HK and Effron, MB (1997). Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. DALLAS: AMER HEART ASSOC.